Trial Profile

Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

06 Dec 2016 Results of pooled analysis of two trials (NCT00416273 and NCT00416208) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
14 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 20th Congress of the European Haematology Association.
02 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com